Introduction
============

In the past few years, there has been a rapid interest in the application of nanoparticles (NPs) in the biochemical sensing,[@b1-ijn-14-243] diagnosis,[@b2-ijn-14-243] and therapy systems.[@b3-ijn-14-243] NPs are expected to play an important role in the formation of several technological,[@b4-ijn-14-243] biological,[@b5-ijn-14-243] and biomedical innovations.[@b6-ijn-14-243] To date, a large number of NPs have been designed and synthesized, especially those made from noble metals NPs.[@b7-ijn-14-243],[@b8-ijn-14-243] Through the potential features of pharmacodynamics and pharmacokinetics, metal NPs can be offered as an excellent candidate in the medicinal chemistry.[@b9-ijn-14-243],[@b10-ijn-14-243] Hence, synthesis and development of unique anticancer[@b11-ijn-14-243],[@b12-ijn-14-243] and antimicrobial drugs derivatives[@b12-ijn-14-243] might be productive in the design of biologically active agents. Zero valent iron (ZVFe) NPs that show unique optical, electronic, and chemical features provide efficient uses in chemistry, biology, and environmental sciences because of suitable surface bioconjugation with molecular probes and significant optical or magnetic properties.[@b13-ijn-14-243] Especially in modern biological researches, ZVFe NPs with the correct substrate could be implemented to take advantage of the degradation potentials of microbial communities.[@b14-ijn-14-243] Also, it has been well documented that ZVFe NPs could increase head and neck cancer cells mortality[@b15-ijn-14-243],[@b16-ijn-14-243] and ovarian cancer cells[@b16-ijn-14-243] through mitochondria-mediated apoptosis or autophagy.

As nanobiomedicine has been developing a growing interest in the application of NPs as anticancer or antimicrobial drugs, determining their adverse effects regarding their impacts on the structural changes of some carrier proteins like human serum albumin (HSA) and cytotoxicity against normal cells become crucially important.[@b17-ijn-14-243]

NPs may become lodged in tissues, and the high durability and reactivity of some NPs raise concerns of their outcomes in the healthy systems.[@b18-ijn-14-243],[@b19-ijn-14-243] Indeed, at this time, not enough data exist to evaluate the biomedical exposure for most engineered NPs. Some NPs that accumulate in animal tissues may have the ability to easily pass through the cell membranes or cross the blood--brain barrier and attack the cells. This may be a potential feature for implementations such as targeted drug delivery and other disorders treatments, but could lead to unintended influences in some cases. Thus, the influence of NPs targeted to human is inevitable as they can come into contact with body through biomedical applications. Furthermore, the small size of NPs is similar to that of most biomacromolecules, and this results in the interaction of NPs with proteins. Therefore, it is vital to explore in advance the detailed interaction mechanism between NPs and biological systems such as cell and proteins before using them as medical agents. For example, Maji et al[@b20-ijn-14-243] showed that plant extract-mediated silver NPs provide potential protein binding and antibacterial and anticancer activities. Karthika et al[@b21-ijn-14-243] reported the fabrication of silver and gold NPs by plant extract and investigated their DNA/protein interactions, anticancer and antimicrobial activities. Khan and Al-Thabaiti[@b22-ijn-14-243] revealed that green-fabricated ZVFe NPs have a strong albumin binding and significant antimicrobial activities.

Therefore, we aimed to fabricate ZVFe NPs with chemical method and investigate their interaction with HSA by biophysical and molecular docking studies. Afterwards, their anticancer and antibacterial effects against human neuroblastoma cell line (SH-SY5Y) and three bacterial strains were investigated, respectively.

HSA is known as a soluble protein in the blood circulatory system showing a number of physiological roles including transporters for a variety of organic and inorganic compounds and controlling the osmotic pressure and pH of blood.[@b23-ijn-14-243] HSA is composed of 585 residues with dominant α-helix conformation, three structural domains (I--III), and numerous efficient drug binding sites.[@b24-ijn-14-243] HSA has been widely used as one of the most extensively studied proteins, not only because of its biomedical significance, low cost, availability, and wide approval in the pharmaceutical industry, but also due to its ligand-binding properties.[@b25-ijn-14-243],[@b26-ijn-14-243]

The white blood cells (WBCs) and SH-SY5Y cells[@b27-ijn-14-243],[@b28-ijn-14-243] are highly sensitive and commonly used for assessing the NP toxicity and their anticancer effects, respectively.

Also, the antibacterial effect of ZVFe NPs was investigated on *Pseudomonas aeruginosa*, *Escherichia coli*, and *Staphylococcus aureus*.

Experimental
============

Synthesis of ZVFe NPs
---------------------

The method of synthesis was modified according to Yuvakkumar et al.[@b29-ijn-14-243] For the synthesis of ZVFe NPs, an aqueous solution of 0.14 M FeSO~4~⋅7H~2~O was dissolved in a 4/1 (v/v) ethanol/water mixture and stirred well with an electric rod for 15 minutes. Then, sodium borohydride solution (100 mL of 0.2 M) was added dropwise into the mixture with gentle stirring for another 30 minutes. The product was separated by centrifugation at 5,000 rpm for 15 minutes and washed three times with ethanol to remove excess borohydrate. Prepared NPs were finally dried under vacuum overnight.

X-ray diffraction analysis
--------------------------

Powder X-ray diffraction (XRD) analysis of ZVFe NP was carried out using Bruker D8 Advance Diffractometer (Bruker AXS, Karlsruhe, Germany) with Cu Kα radiation (λ=1.54 Å) at 45 kV and 40 mA. ZVFe NP was placed in a glass holder and scanned over a 2*θ* range of 20°--80°. Scan rate was 0.5 min^−1^.

Field-emission transmission electron microscope study
-----------------------------------------------------

Field-emission transmission electron microscope (FETEM) analysis of ZVFe NP was carried out using a Philips JSM-6360LA instrument (Philips, Eindhoven, Netherlands). Samples were prepared by sonication for 30 minutes using a sonicator (Misonix S3000).

Dynamic light scattering study
------------------------------

Hydrodynamic diameter, polydispersity index (PDI), and zeta potential of ZVFe with a concentration of 50 µM was measured by using a dynamic light scattering (DLS; Malvern, He/Ne 633 nm laser) at room temperature. For each sample, three independent measurements were done with five scans for each run.

Fluorescence spectroscopy
-------------------------

Fluorescence emission spectra were recorded at three different temperatures of 298, 310, and 315 K on a Cary Eclipse VAR-IAN fluorescence spectrophotometer (Hitachi, Japan). All measurements were carried out at an excitation wavelength of 280 nm and spectral bandwidths of 5 nm. Static fluorescence spectra of HSA and ZVFe NP mixtures were determined in 20 mM phosphate buffer, pH 7.5 at a fixed protein concentration of 2 µM, and varying concentrations (1--15 µM) of ZVFe NP. The spectrum of the buffer and ZVFe NP samples were subtracted from those of protein--NP mixture.

Circular dichroism spectroscopy
-------------------------------

Circular dichroism (CD) spectra were recorded from 190 to 260 nm at 0.2 nm with a scan of rate of 2 points per second at 298 K, with three scans averaged for each CD spectrum. The data were expressed as ellipticity (mdeg), which was obtained in mdeg directly from the instrument. The far CD records of HSA (3 µM) was measured in the absence and presence of varying concentrations of ZVFe NP (3--30 µM), using a spectropolarimeter (model 215; Aviv, Lakewood, NJ, USA). Each record of HSA was subtracted from that of ZVFe NP sample as control.

Thermal melting measurement
---------------------------

The absorbance of HSA as a function of temperature was measured at 295 nm using a UV--visible (UV--vis) spectrophotometer equipped with a thermal bath. The absorbance of HSA (3 µM) in the absence and presence of ZVFe NP (3 M) was recorded as a function of temperature over the range of 30°C--90°C at a heating rate of 1°C min^−1^. The melting temperature (*Tm*) was calculated from the midpoint of the melting curves.

Molecular docking study
-----------------------

The ZVFe NP was clustered in our previous study.[@b30-ijn-14-243] Briefly, geometry of ZVFe was optimized by the CASTEP module in Materials Studio 5.0 developed by Accelrys Software Inc. Local density approximation functional and ultrasoft pseudo potentials were used to model electron--ion interactions. HEX 6.3 software was used to run molecular docking study. Visualization of the ligand site was performed by using CHIMERA ([www.cgl.ucsf.edu/chimera](http://www.cgl.ucsf.edu/chimera)) and PyMOL (<http://pymol.sourceforge.net/>) tools.

Cell culture
------------

SH-SY5Y cell line was purchased from Pasture Institute (Tehran, Iran) and was cultured in plastic tissue culture flasks in Eagle's minimum essential medium and Ham's F12 (1:1) supplemented with 10% FBS and 100 U/mL penicillin--streptomycin--neomycin mixture. The cells were maintained at 37°C in a humidified atmosphere containing 5% CO~2~. WBCs were separated and cultured based on the method reported in our previous paper.[@b31-ijn-14-243] Blood samples were obtained after written informed consent was confirmed in accordance with the Declaration of Helsinki, according to protocol approved by the Ethical Committee of Pharmaceutical Sciences Branch, Islamic Azad University of Tehran, Tehran, Iran.

3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay
--------------------------------------------------------------------

MTT test has been carried out to evaluate cells viability. Following the 24 hours exposure to varying concentrations (1--100 µg/mL) of ZVFe and replacement of the medium, the cells (5×10^3^ per well) were incubated in 37°C for 4 hours with MTT (Sigma-Aldrich, St Louis, MO, USA) solution (0.5 mg/mL). Then, supernatants were gently removed and formazan salt was extracted in DMSO. Measurement of the optical density was performed at 570 nm using a microplate reader (Expert 96, Asys Hitch, Ec Austria). DMSO and NP were used as blank references.

Flow cytometry analysis
-----------------------

Apoptosis induction by ZVFe NPs was assessed by flow cytometric analysis of negative control and ZVFe NPs (IC~50~ concentration) incubated cells according to the manufacturer's protocol (BD Biosciences, San Jose, CA, USA). Briefly, SH-SY5Y cells (3×10^5^ per well) were treated with IC~50~ concentration of ZVFe NPs for 24 hours, collected, washed, and resuspended in 500 µL of 1× Annexin-binding buffer, incubated at room temperature with Annexin V-FITC and PI stain, and analyzed by flow cytometry (BD Biosciences).

Antibacterial assay
-------------------

The antibacterial potential of synthesized ZVFe NP was analyzed initially by well-diffusion method using following Gram-negative and Gram-positive strains of bacteria.

Totally, three bacterial strains, including *P. aeruginosa* (ATCC 27853), *E. coli* (ATCC 25922) as Gram-negative and *S. aureus* (ATCC 25923) as Gram-positive strains, were used for analyzing the antibacterial potential of ZVFe NP. Bacteria were subcultured from pure cultures of different strains of bacteria on Mueller--Hinton Broth for overnight at 37°C. The turbidity of bacterial culture was adjusted to 0.5 McFerland (1.5×10^8^ CFU/mL) standard. Each bacterial strain was swabbed uniformly onto separate Muller--Hinton agar plates using sterile cotton swabs under sterile condition. Wells with 8 mm diameters were prepared by punching a sterile cork borer onto agar plates and removing the agar to form a well. One hundred microliters of 250 µg/mL (w/v) concentration of ZVFe NP were then applied to wells. After incubation for 24 hours, at 35°C--37°C, the zones of inhibition around the wells were measured in millimeter using a caliper. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of ZVFe NP were determined against bacterial strains by the microdilution method.[@b31-ijn-14-243]

Statistical analysis
--------------------

All experiments were carried out in triplicate and data were shown as mean ± SD of three independent experiments. The significance of difference between control- and sample-treated groups was calculated by one-way ANOVA followed by Dunnett's *t*-test using SPSS version 20 (SPSS Inc., Chicago, IL, USA). *P*-value \<0.05 was nominated as the level of significance.

Results and discussion
======================

ZVFe NP characterization
------------------------

The oxidation state and phase of ZVFe NP were analyzed by employing XRD technique ([Figure 1A](#f1-ijn-14-243){ref-type="fig"}). It was shown that the Fe NP was in its zero valent state and no appearance of oxide/hydroxide ligand was revealed on the surfaces of the ZVFe NPs. The peak appearing at 2θ value of \~45° is in good agreement with the value for Fe^0^ reported.[@b32-ijn-14-243]

Particle size was calculated with the XRD by using Scherer equation:[@b32-ijn-14-243] $$D = 0.9\lambda/\beta\cos\theta$$where D is the particle size in Angstrom, λ is the wavelength of radiation, β is the full width at half maximum, and *θ* is the angle obtained from 2*θ* corresponding to maximum peak intensity. The mean crystalline dimension of the ZVFe NP was found to be 37.2 nm.

FESEM is widely employed as a potential technique to detect the size distribution and morphology of particles.[@b33-ijn-14-243] The diameter and morphology of ZVFe NPs are shown in [Figure 1B](#f1-ijn-14-243){ref-type="fig"}. [Figure 1B](#f1-ijn-14-243){ref-type="fig"} demonstrated that the diameter of ZVFe NPs was about 30 nm and NPs exhibited homogeneous and nearly spherical shape. By using DLS, we monitored the hydrodynamic radius of ZVFe NPs at room temperature. DLS exhibits a hydrodynamic radius value of 83.88 nm with a PDI value of 0.21 ([Figure 1C](#f1-ijn-14-243){ref-type="fig"}). Zeta potential value was also obtained from the DLS study. It was determined that the zeta potential value of ZVFe NPs was around −31.91±6.24 mV. These data also confirm the presence of monodispersed ZVFe NPs in the solution and high colloidal stability of the fabricated NPs.

Thermodynamic parameters
------------------------

Fluorescence spectroscopy is a sensitive and simple tool in the protein conformational changes study. Quenching studies utilizing intrinsic Trp fluorescence of proteins can yield important data regarding the microenvironment of the aromatic fluorophore.[@b34-ijn-14-243]--[@b36-ijn-14-243] The quenching mechanism can be classified as dynamic quenching (collisional system) or static quenching (complex formation) between fluorophores and quenchers.[@b37-ijn-14-243] Dynamic and static quenching can be distinguished by their different relations on temperature and viscosity.[@b38-ijn-14-243] The probability of fluorescence quenching with ligands depends on the rate of collision of the quencher and the ground-state fluorophore (static quenching) or excited fluorophore (dynamic quenching).[@b39-ijn-14-243]

As shown in [Figure 2](#f2-ijn-14-243){ref-type="fig"}, the fluorescence intensity of HSA decreases as the ZVFe NP concentration increases at 298 K ([Figure 2A](#f2-ijn-14-243){ref-type="fig"}), 310 K ([Figure 2B](#f2-ijn-14-243){ref-type="fig"}), and 315 K ([Figure 2C](#f2-ijn-14-243){ref-type="fig"}). To determine the mode of quenching and NP-induced conformational changes, further analysis was done.

Mode of interaction
-------------------

Static quenching is invariably related to the temperature, whereas collision quenching is directly related to the temperature. Therefore, fluorescence experiments were performed at three different temperatures (298, 310, and 315 K) to reveal the mode of fluorescence quenching by using the Stern-- Volmer equation ([Equation 1](#fd2-ijn-14-243){ref-type="disp-formula"}):[@b40-ijn-14-243],[@b41-ijn-14-243] $$F_{0}/F_{1} = + K_{SV}\left\lbrack Q \right\rbrack$$where *F*~0~ and *F* exhibit the fluorescence intensities of protein in the absence and presence of the quencher (Q), respectively. In addition, the slope of this plot yields Stern--Volmer constant (*K~SV~*), which is commonly used to reveal the mode of interaction between ligand and protein. The *K~SV~* plot showed straight lines at every studied temperature, which indicates that the Trp residues are embedded at an equal accessible position to the ZVFe NPs ([Figure 3](#f3-ijn-14-243){ref-type="fig"}). The *K*~SV~ values for the interaction of HSA and ZVFe NP are summarized in [Table 1](#t1-ijn-14-243){ref-type="table"}. As shown in [Table 1](#t1-ijn-14-243){ref-type="table"}, when the temperature goes up, the *K~SV~* value decreases, exhibiting a probable static quenching mechanism (complex formation) between HSA and ZVFe NPs.

Binding parameters
------------------

Several equations can be used for calculating the binding constant of the interaction between a protein and a ligand. One of the most routinely used equations is the Hill equation, since it can determine the correct stoichiometry for the binding sites of protein and ligands.[@b42-ijn-14-243] To determine the binding parameters between ZVFe NP and HSA, [Equation 2](#fd3-ijn-14-243){ref-type="disp-formula"} was used:[@b42-ijn-14-243] $$\log\left\lbrack {F_{0} - F/F} \right\rbrack = + \log K_{b}n\log\left\lbrack Q \right\rbrack$$where *K~b~* exhibits the binding constant between protein and NP and *n* shows the number of binding sites. The linear plot of log\[*F*~0~ -- *F*/*F*\] vs log\[Q\] gives rise to the calculation of *K~b~* and *n* from the *y*-intercept and slop of Hill equation, respectively ([Figure 4](#f4-ijn-14-243){ref-type="fig"}). As shown in [Table 2](#t2-ijn-14-243){ref-type="table"}, when the temperature of the system increases, *n* and *K~b~* values reduce, revealing the temperature-induced conformational changes of protein. We infer from these results that the binding site residues in HSA were accessible at 25°C, and buried at around 42°C. Therefore, this binding site moiety is expected to be involved in temperature-induced conformational transitions of HSA.

### Thermodynamic parameters

In general, intermolecular interacting forces between a ligand and a protein include hydrogen bonding, van der Waals interaction, electrostatic forces, and hydrophobic network.[@b43-ijn-14-243] The thermodynamic parameters such as enthalpy change (Δ*H*°), standard entropy change (Δ*S*°), and standard Gibbs free energy change (Δ*G*°) of interaction were determined using van't Hoff equation ([Equation 3](#fd4-ijn-14-243){ref-type="disp-formula"}):[@b43-ijn-14-243] $$LnK_{b} = - \Delta H{^\circ}/RT + \Delta S{^\circ}/R$$where *K~b~* is the binding constant at the corresponding temperature and *R* is the gas constant. By plotting Ln*K~b~* vs 1/T, the Δ*H*° and Δ*S*° can be determined ([Figure 5](#f5-ijn-14-243){ref-type="fig"}; [Table 3](#t3-ijn-14-243){ref-type="table"}). The temperature-dependent thermodynamic parameters for the HSA--ZVFe NP system are used to characterize the intermolecular bonds between protein and NP. The value of Δ*G*° was then calculated by Gibbs--Helmholtz equation ([Equation 4](#fd5-ijn-14-243){ref-type="disp-formula"}):[@b44-ijn-14-243] $$\Delta G{^\circ} = \Delta H{^\circ} - T\Delta S{^\circ}$$

The sign and magnitude of thermodynamic parameters are associated with the involving forces during protein-- ligand interaction. Δ*H*°\>0 and Δ*S*°\>0 exhibit hydrophobic interactions, Δ*H*°\<0 and Δ*S*°\<0 show hydrogen bonds and van der Waals interactions, and Δ*H*°\<0 and Δ*S*°\>0 represent electrostatic interactions.[@b40-ijn-14-243] Negative values of Δ*H*° (−53.21 kJ/mol) and Δ*S*° (−42.44 kJ/mol) showed that the NP-induced conformational changes of protein is induced by an enthalpy-driven manner.[@b40-ijn-14-243] Likewise, Δ*H*°\<0 and Δ*S*°\<0 are characteristics of hydrogen bonds and van der Waals interactions in aqueous solution. Due to the large surface-to-volume-ratio of NPs, water molecules are substantially adsorbed on their surface and can mediate the establishment of hydrogen bonds between NP and protein.

Water is an extremely good acceptor and donator of hydrogen bonds. So, if a protein is partially unfolded in solution due to its interaction with NP, geometrically perfect hydrogen bonds can be formed with a very polarized molecule, water, on the surface of NP.

Secondary structural studies
----------------------------

Due to the influence of NP on the spectra of HSA, it is crucial to determine the structural changes of HSA in the presence of ZVFe NP. CD is a sensitive technique to monitor the secondary structural changes of protein.[@b45-ijn-14-243] Far UV--CD (190--260 nm) spectra of HSA and HSA--ZVFe NP are shown in [Figure 6](#f6-ijn-14-243){ref-type="fig"}. In HSA spectrum, there are two bands in the UV region, at 208 and 222 nm, which are characteristic of the α-helical conformation of HSA. Both transitions at 208 and 222 nm are known as a broad n→π^\*^ transition for the peptide bond of the α-helix.[@b46-ijn-14-243] [Figure 6](#f6-ijn-14-243){ref-type="fig"} shows that the spectra obtained for HSA in the presence of various concentrations of ZVFe NPs were also similar to the spectrum of HSA in the absence of NPs. Therefore, it can be concluded that the relative α-helix structure of HSA remains unchanged in the presence of ZVFe NP.

UV--vis spectroscopy study
--------------------------

UV--vis absorption measurements are commonly used to investigate structural changes of proteins and complex formation.[@b47-ijn-14-243] Thermal behaviors of HSA in the absence and presence of ZVFe NP can provide detailed information about the interaction strength of NPs with proteins. It is well known that, when the temperature in the solution goes up, the folded state of protein shifts toward the denatured structure and generates a hyperchromic influence on the absorption spectra of protein residues. In order to reveal this transition process, the *Tm* point, which is defined as the temperature, where half of the total native protein are denatured, is usually introduced.

The melting curves of HSA at 295 nm in the absence and presence of ZVFe NPs are presented in [Figure 7](#f7-ijn-14-243){ref-type="fig"}. Here, the thermal denaturation experiment revealed *Tm* values of around 64°C and 65°C for HSA in the presence and absence of the ZVFe NP, respectively. These almost identical values of Tm for HSA in the absence and presence of ZVFe NP are in good agreement with CD data. Therefore, it may be concluded that HSA structure remains almost unchanged after interaction with ZVFe NPs.

Molecular docking study
-----------------------

Molecular docking study was carried out to support the experimental data indicating that hydrogen bonds are the main forces in the interaction of HSA with ZVFe NPs. The X-ray crystallographic 3D structure of HSA at 2.5 A resolution (Protein Data Bank \[PDB\] ID: 1AO6) was downloaded from the online protein data bank Research Collaboratory for Structural Bioinformatics (RCSB) PDB (<http://www.pdb.org>).[@b48-ijn-14-243] The molecular docking was performed with designed ZVFe cluster. The resulting E-value was found to be −280.64. The docked complex is shown in [Figure 8](#f8-ijn-14-243){ref-type="fig"}. The ligand with surrounding active site residues within 3.5 Å is given in [Figure 9A--C](#f9-ijn-14-243){ref-type="fig"}. The nearest interacting residues are SER-517, ASP-173, ASP-183, ARG-114, LEU-115, VAL-116, ARG-117, LYS-519, GLU-520, LYS-519, and ARG-186. These residues possess hydroxyl, carboxyl, and amine groups, which provide a potential medium to form hydrogen bonds with water molecules on ZVFe NP surface. Indeed, it may be indicated that the type of interaction between NPs and macromolecules depends on a number of factors, such as concentration, pH, temperature, and type of NPs/proteins. Actually, the type of interaction between NPs and proteins can be weakened or strengthened by changing these factors. It seems ZVFe NPs form hydrogen bonds and van der Waals interaction with HSA, which are known as relatively weak forces. Therefore, these interactions do not induce substantial conformational changes on the HSA structure.

MTT assay
---------

Different cells were employed to reveal the in vitro cytotoxic effect of ZVFe NPs. SH-SY5Y and WBCs were incubated with different concentrations (1, 10, 20, 30, 50, 100 µg/mL) of ZVFe NPs for 24 hours. Cell viability was then assessed by MTT assay. It was observed that ZVFe NPs induced mortality of cancer cells ([Figure 10](#f10-ijn-14-243){ref-type="fig"}) and growth inhibitions were 95.37%±14.02%, 86.13%±19.27%, 73.31%±11.87% (*P*\<0.05), 64.19%±15.16% (*P*\<0.05), 48.21%±17.62% (*P*\<0.01), and 39.11%±12.51% (*P*\<0.01) in SH-SY5Y cells after treatment with 1, 10, 20, 30, 50, and 100 µg/mL of ZVFe NPs, respectively. However, it was revealed that the WBCs viability was 98%±19.05%, 96%±8.68%, 95%±12.16%, 91%±10.66%, 88%±8.09%, and 75%±3.97% (*P*\<0.05), after treatment with 1, 10, 20, 30, 50, and 100 µg/mL of ZVFe NPs, respectively. As presented in [Figure 10](#f10-ijn-14-243){ref-type="fig"}, some cytotoxic activity was already revealed at 20 µg/mL dose of ZVFe NPs on SH-SY5Y cells, whereas maximal effect was obtained at a concentration of 100 µg/mL in WBCs. Therefore, it was concluded that ZVFe NPs with concentrations of \<100 µg/mL did not induce cytotoxicity on normal cells, so they could be used as potential candidates to act as nontoxic drug carriers or anticancer agents. The IC~50~ concentration of ZVFe NPs against SH-SY5Y cells and WBCs were calculated to be 47.89±81 µg/mL and \>100 µg/mL, respectively. In fact, the nano state of ZVFe intensified the difference between cytotoxicity outcome in cancer and normal cells. Based on these observations, the present paper focused on SH-SY5Y cells for subsequent assays.

Quantification of apoptosis
---------------------------

Quantification of apoptosis induction by ZVFe NPs on SH-SY5Y cells (IC~50~ concentration) was carried out by using flow cytometry. [Figure 11](#f11-ijn-14-243){ref-type="fig"} displays the ZVFe NPs-triggered apoptosis in SH-SY5Y cells after 24 hours incubation at IC~50~ concentration. The flow cytometry analysis results indicated that the rate of early apoptosis (Q3), late apoptosis (Q2), and necrosis (Q1) in control cells were 1.14%, 1.07%, and 2.48%, respectively ([Figure 11A](#f11-ijn-14-243){ref-type="fig"}). However, treatment of the SH-SY5Y cells with IC~50~ concentration of ZVFe NPs for 24 hours enhanced the rate of early apoptosis (8.99%, *P*\<0.001), late apoptosis (14.94%, *P*\<0.001), and necrosis (6.3%, *P*\<0. 01; [Figure 11B](#f11-ijn-14-243){ref-type="fig"}).

Antibacterial assay
-------------------

The antibacterial activity of ZVFe NP against one Gram-positive and two Gram-negative strains of bacteria are illustrated in [Figure 12](#f12-ijn-14-243){ref-type="fig"}. Also, the inhibition zone diameter of ZVFe NP against *E. coli*, *P. aeruginosa*, and *S. aureus* is displayed in [Figure 13](#f13-ijn-14-243){ref-type="fig"}. The results showed a noteworthy inhibitory effect of ZVFe NPs on both bacterial strains. [Table 4](#t4-ijn-14-243){ref-type="table"} shows the MIC and MBC of ZVFe NP against three strains of bacteria. It was observed that ZVFe NP induced strong antibacterial effect against *E. coli*, *P. aeruginosa*, and *S. aureus* with an MIC of 1.96, 31.25, and 15.75 µg/mL, respectively. The MBC observed in the present study was 1.96 µg/mL for *E. coli*, 31.25 µg/mL for *S. aureus*, and 62.5 µg/mL for *P. aeruginosa*.

Discussion
==========

In pharmaceutical industry, it is critical to determine and specify the pharmacokinetics and pharmacological influence of drugs like NPs.[@b49-ijn-14-243],[@b50-ijn-14-243] It is invariably assumed that the probable influence of drugs (NPs) heavily depends on their binding affinity to carrier proteins such as albumin.[@b51-ijn-14-243] The interaction of NPs with proteins also affects the rate at which the NPs are delivered to targeted sites of reaction.[@b52-ijn-14-243] Hence, analyzing the interaction of NPs with albumin is essential not only because the unbound NPs may affect a number of overcritical pharmacokinetic constants including the constant distribution volume, but also because it provides a crucial effect to express the administration regimen dose.[@b53-ijn-14-243] Hence, it is important to examine that albumin can eventually influence the NP's absorption, tissue distribution and pharmacodynamics, metabolism, and excretion features. In addition, the application of NPs, which can enter the body through the different routes and can interact with the albumin, could alter the conformation of albumin.

Uncontrolled side effects such as pH, temperature, and other denaturing conditions can influence the binding of an NP to albumin.[@b54-ijn-14-243] Indeed, conformational changes of protein in the presence of NPs can weaken or strengthen the binding affinity of proteins to NPs. Furthermore, a comprehensive characterization of albumin in the presence of NPs and thermodynamic parameters is also necessary not only for understanding its pivotal physiological features, but also most recently to develop nanosystems as targeted delivery vehicles for several therapeutic and diagnostic NPs. Hence, the data about NP--protein interaction may provide potential and central details in the field of nanomedicine.

We showed that ZVFe NP binds to HSA through hydrogen bonds and does not play a significant role in the structural changes of HSA. The reason that hydrogen bonds do not induce a net destabilizing/stabilizing impact on protein conformation lies in the fact that in order to establish protein--NPs hydrogen bonds, another set of hydrogen bonds on the surface of protein should be disrupted.[@b55-ijn-14-243] Interaction of protein with NP causes destabilization of protein conformation and exposure of the hydrophobic core. Contacting the dipoles that form the hydrogen bonds with these hydrophobic patches is energetically unfavorable. So, the overall effect of hydrogen bonds in NP-induced conformational alterations of proteins is that of inducing structural destabilization, not denaturation.

Biophysical study of zinc oxide interaction with albumin demonstrated no structural perturbation in the secondary structure of protein; however, some minor tertiary changes were reported.[@b56-ijn-14-243] Gold NPs were indicated to cause conformational changes in the structure of albumin in a dose-dependent manner,[@b57-ijn-14-243] whereas no major conformational change was reported for albumin when adsorbed onto the carbon C60 fullerene NP.[@b58-ijn-14-243] The interaction of magnetic iron oxide NPs with albumin was also investigated by spectroscopic methods.[@b59-ijn-14-243] The results indicated that the interaction was spontaneous and the electrostatic interactions played key roles in the interaction process. In addition, secondary structural alteration of albumin in the presence of MNPs was shown. It seems that the chemical composition of NPs may play an important role in inducing conformational changes of proteins upon interaction.

One of the crucial challenges in the development of anticancer drugs is increasing the therapeutic effectiveness of anticancer NPs and minimizing their side effects on normal cells. In our MTT assay, ZVFe NPs demonstrated a broad range of cytotoxicity with most mortality effect on SH-SY5Y cells but not on normal WBCs. Although, the mechanism of cancer-specific toxicity of ZVFe NPs is still unknown, this selective killing effect of ZVFe NPs in cancer cells is clinically important. Recently, selectivity in killing a wide spectrum of cancer cells by NPs including zinc oxide NPs,[@b60-ijn-14-243] iron oxide NPs,[@b61-ijn-14-243] and copper oxide NPs[@b62-ijn-14-243] has been reported.

However, oxidative stress induced by ZVFe NPs in human bronchial epithelial cells has been reported.[@b63-ijn-14-243] Therefore, these conflicting results may suggest that further studies should be done to explore the mechanisms behind the cytotoxic effects of NPs.

The effect of ZVFe NPs on bacterial activity was also investigated. The synthesized ZVFe NPs showed a noteworthy inhibitory effect on tested pathogenic bacteria. Based on these findings, bactericidal action of ZVFe NPs was affective. The different sensitivities of Gram-positive and Gram-negative bacteria against ZVFe NPs could be explained in accordance with the morphological differences between these microorganisms, due to different polarities of their cell wall. Other studies have demonstrated that the size of NPs can also affect their bactericidal activities. For example, Lee et al[@b64-ijn-14-243] reported that the inactivation of *E. coli* by ZVFe NPs could be induced by infiltration of the NPs through *E. coli* membranes. A number of other investigations on zinc oxide[@b65-ijn-14-243],[@b66-ijn-14-243] and magnesium oxide NPs[@b67-ijn-14-243] have also shown that antibacterial activity of NPs depend on their dimension.

In this study, the size of ZVFe NPs was about 30 nm, which enabled the NPs to cross the cell membrane and induce some adverse effects on the viability of bacteria. It may be suggested that ZVFe NPs could interact with intracellular oxygen, causing oxidative stress induction and finally driving cell membrane leakage.[@b64-ijn-14-243] Herein, the concentration of ZVFe NPs was also a crucial factor to induce bactericidal activity against pathogenic bacteria. This behavior was reported by other studies when they explored the antimicrobial impacts of silver,[@b68-ijn-14-243] zinc oxide,[@b65-ijn-14-243] and iron oxide[@b69-ijn-14-243] NPs on *S. aureus* and *E. coli*. Also, it should be noted that the fabrication route of NPs also influences the bactericidal activity. Indeed, different synthetic methods can form different NPs with various physicochemical and antibacterial properties.[@b70-ijn-14-243]

Conclusion
==========

The results of this study indicate that ZVFe NPs potentially bind to HSA through hydrogen bonds and van der Waals interactions and induce marginal structural changes on the HSA structure. Cytotoxicity assay revealed the selective killing of cancer cells by ZVFe NPs. Antibacterial examination showed that ZVFe NPs provide a potential antibacterial effect against *E. coli*, *P. aeruginosa*, and *S. aureus*.

Therefore, it may be concluded that ZVFe NP may be used in medicine as a potential anticancer and/or antibacterial drug. However, it should be noted that some in vivo studies are required to more explore the anticancer and antibacterial activities of ZVFe NPs.
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![The XRD pattern of ZVFe NP (**A**); FESEM image of ZVFe NPs (**B**); DLS histogram of ZVFe NPs (**C**).\
**Abbreviations:** DLS, dynamic light scattering; FESEM, field-emission scanning electron microscope; XRD, X-ray diffraction; ZVFe NPs, zero valent iron nanoparticles.](ijn-14-243Fig1){#f1-ijn-14-243}

![Fluorescence quenching of HSA upon interaction with ZVFe NP at three different temperatures: 298 K (**A**), 310 K (**B**), and 315 K (**C**).\
**Note:** The fluorescence spectra of HSA (2 µM) in the presence of varying concentrations (0 \[dark blue\], 1 \[brown\], 2 \[green\], 4 \[bright blue\], 6 \[purple\], 8 \[gray\], 10 \[bright brown\], and 15 \[red\] µM) of ZVFe NPs.\
**Abbreviations:** HSA, human serum albumin; ZVFe NPs, zero valent iron nanoparticles.](ijn-14-243Fig2){#f2-ijn-14-243}

![Stern--Volmer plot of the fluorescence quenching of HSA (2 µM) in the presence of varying concentrations (1, 2, 4, 6, 8, 10, and 15 µM) of ZVFe NPs at 298 K (■), 310 K (♦), and 315 K (▲).\
**Abbreviations:** HSA, human serum albumin; ZVFe NPs, zero valent iron nanoparticles.](ijn-14-243Fig3){#f3-ijn-14-243}

![Hill plot for the binding of HSA with ZVFe NPs at 298 K (■), 310 K (♦), and 315 K (▲).\
**Abbreviations:** HSA, human serum albumin; ZVFe NPs, zero valent iron nanoparticles.](ijn-14-243Fig4){#f4-ijn-14-243}

![Van't Hoff plot for the binding of HSA with ZVFe NPs.\
**Abbreviations:** HSA, human serum albumin; ZVFe NPs, zero valent iron nanoparticles.](ijn-14-243Fig5){#f5-ijn-14-243}

![Far CD spectra of HSA (3 µM) in the presence of varying concentrations of ZVFe NP (0 \[black\], 3 \[red\], 10 \[blue\], and 30 \[green\] µM).\
**Abbreviations:** CD, circular dichroism; HSA, human serum albumin; ZVFe NPs, zero valent iron nanoparticles.](ijn-14-243Fig6){#f6-ijn-14-243}

![The absorbance (295 nm) of HSA (3 µM) in the absence (blue line) and presence (red line) of ZVFe NP (3 M) over the temperature range of 30°C--90°C.\
**Abbreviations:** HSA, human serum albumin; ZVFe NPs, zero valent iron nanoparticles.](ijn-14-243Fig7){#f7-ijn-14-243}

![Molecular docking of HSA with water-coated ZVFe NP.\
**Abbreviations:** HSA, human serum albumin; ZVFe NPs, zero valent iron nanoparticles.](ijn-14-243Fig8){#f8-ijn-14-243}

![Different views (**A**--**C**) of the ligand and its surrounding site residues.](ijn-14-243Fig9){#f9-ijn-14-243}

![The viability percent of SH-SY5Y (blue bars) cells and WBCs (red bars) in the presence of varying concentrations of ZVFe NPs after 24 hours.\
**Note:** ^\*^*P*\<0.05 and ^\*\*^*P*\<0.01 represent the significant differences between ZVFe NPs-treated groups and control.\
**Abbreviations:** WBCs, white blood cells; ZVFe NPs, zero valent iron nanoparticles.](ijn-14-243Fig10){#f10-ijn-14-243}

![Flow cytometry analysis of ZVFe NP-induced apoptosis.\
**Notes:** The induction of apoptosis was observed by IC~50~ concentration of ZVFe NPs (47.89±81 µg/mL) on SH-SY5Y cell. (**A**) Control cells and (**B**) treated group.\
**Abbreviation:** ZVFe NPs, zero valent iron nanoparticles.](ijn-14-243Fig11){#f11-ijn-14-243}

![(**A**--**C**) Photographs of the zone of inhibition produced by ZVFe NP against three strains of bacteria.\
**Note:** (**A**) *Escherichia coli*, (**B**) *Pseudomonas aeruginosa*, and (**C**) *Staphylococcus aureus*.\
**Abbreviation:** ZVFe NPs, zero valent iron nanoparticles.](ijn-14-243Fig12){#f12-ijn-14-243}

![The antibacterial activity of ZVFe NPs aganist *E.coli*, *P. aeruginosa* and *S. aureus* bacterial strains tested by disc diffusion method. (Measuring inhibition zone diameter \[mm\]).](ijn-14-243Fig13){#f13-ijn-14-243}

###### 

*K~SV~* parameters at three different temperatures for the interaction of HSA with ZVFe NPs

  *T* (K)   *K~SV~*             *R*^2^
  --------- ------------------- --------
                                
  298       3.37±0.58×10^5^     0.99
  310       2.53.3±0.39×10^5^   0.95
  315       1.33.3±0.18×10^5^   0.94

**Abbreviations:** HSA, human serum albumin; ZVFe NPs, zero valent iron nanoparticles.

###### 

Binding parameters at three different temperatures for the interaction of HSA with ZVFe NPs

  *T* (K)   *n*    *K~b~*   *R*^2^
  --------- ------ -------- --------
                            
  298       1.05   5.74     0.99
  310       0.82   4.56     0.96
  315       77     3.79     0.91

**Abbreviations:** HSA, human serum albumin; ZVFe NPs, zero valent iron nanoparticles.

###### 

Thermodynamic parameters at three different temperatures for the interaction of HSA with ZVFe NPs

  *T* (K)   Δ*G* (kJ/mol)   Δ*H* (kJ/mol)   TΔ*S* (kJ/mol)
  --------- --------------- --------------- ----------------
                                            
  298       −32.42                          −171,654.126
  310       −26.63          −204.080        −177,449.85
  315       −22.24                          −181,831.005

**Abbreviations:** HSA, human serum albumin; ZVFe NPs, zero valent iron nanoparticles.

###### 

MIC and MBC of ZVFe NP against three strains of bacteria

  Bacteria                   MIC (µg/mL)   MBC (µg/mL)
  -------------------------- ------------- -------------
                                           
  *Staphylococcus aureus*    15.75±1.77    31.25±1.50
  *Escherichia coli*         1.96±0.80     1.96±0.50
  *Pseudomonas aeruginosa*   31.25±0.80    62.5±0.50

**Note:** Data presented as mean ± SD.

**Abbreviations:** MBC, minimum bactericidal concentration; MIC, minimum inhibitory concentration; ZVFe NPs, zero valent iron nanoparticles.
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